Analysts Split on Intuitive Surgical, Inc. (ISRG) Valuation Despite Strong Operating Momentum

We recently compiled a list of the 20 Most Profitable Stocks of the Last 20 Years. Intuitive Surgical, Inc. is one of the most profitable stocks on our list.

TheFly reported on January 23 that Evercore ISI analyst Vijay Kumar lowered the price target on ISRG to $550 from $580 while maintaining an In Line rating. The analyst said the company’s performance was largely in line with expectations, with notable beats in both revenue and EPS driven by strong system placements and procedure growth.

In contrast, on the same day, Piper Sandler raised its price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $620 from $610 and maintained an Overweight rating. The firm said that ISRG’s Q4 revenue and earnings exceeded consensus projections. According to the analyst, management reiterated the 2026 procedural guidelines it had previously published.

Additionally, the company said on the same day that da Vinci robotic systems have now performed surgery on over 20 million patients globally. Over 3.1 million da Vinci procedures were carried out worldwide by the end of 2025, marking the achievement of this milestone. This reflected continued adoption and expanded patient access toISRG’s technology.

Intuitive Surgical, Inc. (NASDAQ:ISRG) is a U.S. medical technology company that designs, manufactures, and markets robotic systems for minimally invasive surgery. Its flagship da Vinci Surgical System and Ion endoluminal platform help physicians perform complex procedures with precision.

While we acknowledge the potential of ISRG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.